Emerging treatments for pemphigoid diseases

Trends in Molecular Medicine

Volumn 19, Issue 8, 2013, Pages 501-512

  Ludwig, Ralf J ^a   Kalies, Kathrin ^a   Köhl, Jörg ^a,b   Zillikens, Detlef ^a   Schmidt, Enno ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Autoimmune skin blistering; Autoimmunity; Cytokine; Fc receptor; IgE; Skin; Treatment

Indexed keywords

ALPHA6BETA4 INTEGRIN; AUTOANTIBODY; AUTOANTIGEN; CD3 ANTIBODY; CD40 ANTIGEN; CORTICOSTEROID; DACETUZUMAB; EPITOPE; FC RECEPTOR; GAMMA INTERFERON; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 4; KALININ; MONOCLONAL ANTIBODY; NI 0501; OTELIXIZUMAB; REACTIVE OXYGEN METABOLITE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 4; RUPLIZUMAB; STRUCTURAL PROTEIN; TEPLIZUMAB; TORALIZUMAB; UNCLASSIFIED DRUG; ZANOLIMUMAB;

BASEMENT MEMBRANE; BULLOUS PEMPHIGOID; DERMOEPIDERMAL JUNCTION; DISEASE SEVERITY; DRUG MEGADOSE; ENDOCRINE OPHTHALMOPATHY; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE ACTIVATION; LICHEN PLANUS; LYMPHOCYTE; MORTALITY; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE SCLEROSIS; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PATHOGENICITY; PEMPHIGOID; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; SURVIVAL RATE; T CELL LYMPHOMA;

EID: 84881027363     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.06.003     Document Type: Review

References (117)

1. Schmidt E., Zillikens D. Pemphigoid diseases. Lancet 2013, 381:320-332.
2. Joly P., et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N. Engl. J. Med. 2002, 346:321-327.
3. Joly P., et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J. Invest. Dermatol. 2009, 129:1681-1687.
4. Cortes B., et al. Mortality of bullous pemphigoid in Switzerland: a prospective study. Br. J. Dermatol. 2011, 165:368-374.
5. Langan S.M., et al. Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study. BMJ 2008, 337:a180.
6. Bertram F., et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J. Dtsch. Dermatol. Ges. 2009, 7:434-440.
7. Gupta R., et al. Epidermolysis bullosa acquisita. Clin. Dermatol. 2012, 30:60-69.
8. Chan L.S. Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid). Clin. Dermatol. 2012, 30:34-37.
9. Woodley D.T., et al. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N. Engl. J. Med. 1984, 310:1007-1013.
10. Ludwig R.J. Model systems duplicating epidermolysis bullosa acquisita: a methodological review. Autoimmunity 2012, 45:102-110.
11. Dainichi T., et al. Anti-laminin γ-1 pemphigoid. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2800-2805.
12. Marinkovich M.P., et al. LAD-1 is absent in a subset of junctional epidermolysis bullosa patients. J. Invest. Dermatol. 1997, 109:356-359.
13. Lazarova Z., et al. Fab fragments directed against laminin 5 induce subepidermal blisters in neonatal mice. Clin. Immunol. 2000, 95:26-32.
14. Vafia K., et al. Pathogenicity of autoantibodies in anti-p200 pemphigoid. PLoS ONE 2012, 7:e41769.
15. Heimbach L., et al. Experimental animal models of bullous pemphigoid. G. Ital. Dermatol. Venereol. 2009, 144:423-431.
16. Chen M., et al. Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen. Autoimmunity 2011, 45:91-101.
17. Gammon W.R., et al. Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. J. Invest. Dermatol. 1988, 91:228-232.
18. Delgado J.C., et al. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:8569-8571.
19. Zumelzu C., et al. Black patients of African descent and HLA-DRB1*15:03 frequency overrepresented in epidermolysis bullosa acquisita. J. Invest. Dermatol. 2011, 131:2386-2393.
20. Ludwig R.J., et al. Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita. J. Invest. Dermatol. 2011, 131:167-176.
21. Ludwig R.J., et al. Identification of quantitative trait loci in experimental epidermolysis bullosa acquisita. J. Invest. Dermatol. 2012, 132:1409-1415.
22. Sitaru A.G., et al. T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa acquisita. J. Immunol. 2010, 184:1596-1603.
23. Ujiie H., et al. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen. J. Immunol. 2010, 184:2166-2174.
24. + T cells play a pivotal role in the development of active disease in experimental bullous pemphigoid model. Clin. Immunol. 2012, 142:167-175.
25. Kuo T.T., et al. Neonatal Fc receptor: from immunity to therapeutics. J. Clin. Immunol. 2013, 30:777-789.
26. Li N., et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J. Clin. Invest. 2005, 115:3440-3450.
27. Sesarman A., et al. Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita. J. Mol. Med. (Berl.) 2008, 86:951-959.
28. Liu Z., et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J. Clin. Invest. 1993, 92:2480-2488.
29. Ishii N., et al. Autoantibody-induced intestinal inflammation and weight loss in experimental epidermolysis bullosa acquisita. J. Pathol. 2011, 224:234-244.
30. Ludwig R.J., Zillikens D. Pathogenesis of epidermolysis bullosa acquisita. Dermatol. Clin. 2011, 29:493-501.
31. Liu Z., et al. Differential roles for β2 integrins in experimental autoimmune bullous pemphigoid. Blood 2006, 107:1063-1069.
32. Chiriac M.T., et al. NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage. J. Pathol. 2007, 212:56-65.
33. Zhao M., et al. Role of FcRs in animal model of autoimmune bullous pemphigoid. J. Immunol. 2006, 177:3398-3405.
34. Kasperkiewicz M., et al. Genetic identification and functional validation of FcγRIV as key molecule in autoantibody-induced tissue injury. J. Pathol. 2012, 228:8-19.
35. Liu Z., et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J. Clin. Invest. 2000, 105:113-123.
36. Shimanovich I., et al. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J. Pathol. 2004, 204:519-527.
37. Chatenoud L., et al. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:123-127.
38. Keymeulen B., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 2005, 352:2598-2608.
39. Kim Y.H., et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007, 109:4655-4662.
40. Wendling D., et al. A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis. J. Rheumatol. 1998, 25:1457-1461.
41. Nissler K., et al. Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen induced arthritis: influence on macrophage activation. Ann. Rheum. Dis. 2004, 63:1470-1477.
42. Hammers C.M., et al. Complement-fixing anti-type VII collagen antibodies are induced in Th1-polarized lymph nodes of epidermolysis bullosa acquisita-susceptible mice. J. Immunol. 2011, 187:5043-5050.
43. Nakama T., et al. Efficacy of interferon-γ in patients with refractory bullous pemphigoid. J. Dermatol. 2007, 34:737-745.
44. Arakawa M., et al. Lesional Th17 cells and regulatory T cells in bullous pemphigoid. Exp. Dermatol. 2011, 20:1022-1024.
45. Miossec P., Kolls J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug Discov. 2012, 11:763-776.
46. Kasperkiewicz M., et al. Heat shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that non-malignant plasma cells are not therapeutic targets. Blood 2011, 117:6135-6142.
47. Ujiie H., et al. Pathogenesis of bullous pemphigoid. Dermatol. Clin. 2011, 29:439-446.
48. Patel H.J., et al. Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opin. Drug Discov. 2011, 6:559-587.
49. Bhushan A., Covey L.R. CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes. Immunol. Res. 2001, 24:311-324.
50. Levesque M.C. Translational mini-review series on B cell-directed therapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin. Exp. Immunol. 2009, 157:198-208.
51. Patel D.A., et al. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. J. Immunol. 2011, 187:1015-1022.
52. Messingham K.N., et al. Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies. G. Ital. Dermatol. Venereol. 2012, 147:251-257.
53. Binstadt B.A., et al. Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat. Immunol. 2006, 7:284-292.
54. Di Zenzo G., et al. Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J. Invest. Dermatol. 2011, 131:2271-2280.
55. Zillikens D., et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J. Invest. Dermatol. 1997, 109:573-579.
56. Nishie W., et al. Humanization of autoantigen. Nat. Med. 2007, 13:378-383.
57. Wang G., et al. Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigen. Am. J. Pathol. 2010, 176:914-925.
58. Li Q., et al. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model. J. Immunol. 2010, 185:7746-7755.
59. Hirose M., et al. Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen. J. Autoimmun. 2012, 39:304-314.
60. Bosch T. Therapeutic apheresis - state of the art in the year 2005. Ther. Apher. Dial. 2005, 9:459-468.
61. Nagatomo Y., et al. Specific immunoadsorption therapy using a tryptophan column in patients with refractory heart failure due to dilated cardiomyopathy. J. Clin. Apher. 2011, 26:1-8.
62. Meyersburg D., et al. Immunoadsorption in dermatology. Ther. Apher. Dial. 2012, 16:311-320.
63. Liu Z., et al. The role of complement in experimental bullous pemphigoid. J. Clin. Invest. 1995, 95:1539-1544.
64. Sitaru C., et al. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J. Clin. Invest. 2005, 115:870-878.
65. Hillmen P., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 2006, 355:1233-1243.
66. Stegall M.D., et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. 2011, 11:2405-2413.
67. Köhl J. Drug evaluation: the C5a receptor antagonist PMX-53. Curr. Opin. Mol. Ther. 2006, 8:529-538.
68. Qu H., et al. Recent developments in low molecular weight complement inhibitors. Mol. Immunol. 2009, 47:185-195.
69. Otto M., et al. C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. J. Biol. Chem. 2004, 279:142-151.
70. Karsten C.M., et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nat. Med. 2012, 18:1401-1406.
71. Heffernan M.P., Bentley D.D. Successful treatment of mucous membrane pemphigoid with infliximab. Arch. Dermatol. 2006, 142:1268-1270.
72. John H., et al. Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-α. Eye (Lond.) 2007, 21:1434-1435.
73. Kennedy J.S., et al. Recalcitrant cicatricial pemphigoid treated with the anti-TNF-α agent etanercept. J. Drugs Dermatol. 2010, 9:68-70.
74. Boussemart L., et al. Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology 2010, 221:201-205.
75. Schmidt E., et al. Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J. Invest. Dermatol. 2000, 115:842-848.
76. Scheller J., et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 2011, 1813:878-888.
77. Samavedam U.K., et al. Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. J. Autoimmun. 2013, 40:74-85.
78. Chen R., et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J. Clin. Invest. 2001, 108:1151-1158.
79. Liu Z., et al. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J. Autoimmun. 2008, 31:331-338.
80. Schön M.P., Ludwig R.J. Lymphocyte trafficking to inflamed skin - molecular mechanisms and implications for therapeutic target molecules. Expert Opin. Ther. Targets 2005, 9:225-243.
81. Liu Z., et al. A major role for neutrophils in experimental bullous pemphigoid. J. Clin. Invest. 1997, 100:1256-1263.
82. Harris E.S., et al. The leukocyte integrins. J. Biol. Chem. 2000, 275:23409-23412.
83. Carlow D.A., et al. PSGL-1 function in immunity and steady state homeostasis. Immunol. Rev. 2009, 230:75-96.
84. Staite N.D., et al. Inhibition of delayed-type contact hypersensitivity in mice deficient in both E-selectin and P-selectin. Blood 1996, 88:2973-2979.
85. Tedder T.F., et al. L-Selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites. J. Exp. Med. 1995, 181:2259-2264.
86. Hirata T., et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is a physiological ligand for E-selectin in mediating T helper 1 lymphocyte migration. J. Exp. Med. 2000, 192:1669-1676.
87. Alban S., et al. PS3, a semisynthetic β-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions. J. Invest. Dermatol. 2009, 129:1192-1202.
88. Oostingh G.J., et al. Diminished lymphocyte adhesion and alleviation of allergic responses by small-molecule- or antibody-mediated inhibition of L-selectin functions. J. Invest. Dermatol. 2007, 127:90-97.
89. Schön M.P., et al. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat. Med. 2002, 8:366-372.
90. Nimmerjahn F., Ravetch J.V. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47.
91. Yu X., et al. FcγRIIA and FcγRIIIB are required for autoantibody-induced tissue damage in experimental human models of bullous oemphigoid. J. Invest. Dermatol. 2010, 30:2841-2844.
92. Weisenseel P., et al. Relevance of the low-affinity type of the Fcγ-receptor IIIa-polymorphism in bullous pemphigoid. Arch. Dermatol. Res. 2007, 299:163-164.
93. Johnson S.A., et al. Phosphorylated immunoreceptor signaling motifs (ITAMs) exhibit unique abilities to bind and activate Lyn and Syk tyrosine kinases. J. Immunol. 1995, 155:4596-4603.
94. Kulkarni S., et al. Essential role for PI3Kβ in neutrophil activation by immune complexes. Sci. Signal. 2011, 4:ra23.
95. Sondermann P., Jacob U. Human Fcγ receptor IIb expressed in Escherichia coli reveals IgG binding capability. Biol. Chem. 1999, 380:717-721.
96. Werwitzke S., et al. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fcγ receptor II (CD32). Ann. Rheum. Dis. 2008, 67:154-161.
97. Magnusson S.E., et al. Amelioration of collagen-induced arthritis by human recombinant soluble FcγRIIb. Clin. Immunol. 2008, 127:225-233.
98. Coffey G., et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J. Pharmacol. Exp. Ther. 2012, 340:350-359.
99. Bahjat F.R., et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 2008, 58:1433-1444.
100. Hellberg L., et al. Methylprednisolone blocks autoantibody-induced tissue damage through inhibition of neutrophil activation. J. Invest. Dermatol. 2013, 10.1038/jid.2013.91.
101. Zarbock A., Ley K. Neutrophil adhesion and activation under flow. Microcirculation 2009, 16:31-42.
102. Koppula S., et al. Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson's disease. Mediators Inflamm. 2012, 2012:823902.
103. Miesel R., et al. Antiinflammatory effects of NADPH oxidase inhibitors. Inflammation 1995, 19:347-362.
104. Lin L., et al. Neutrophil elastase cleaves the murine hemidesmosomal protein BP180/type XVII collagen and generates degradation products that modulate experimental bullous pemphigoid. Matrix Biol. 2012, 31:38-44.
105. Kopecki Z., et al. Overexpression of the Flii gene increases dermal-epidermal blistering in an autoimmune ColVII mouse model of epidermolysis bullosa acquisita. J. Pathol. 2011, 225:401-413.
106. Kopecki Z., et al. Topically applied flightless I neutralising antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita. J. Invest. Dermatol. 2013, 133:1008-1016.
107. Ren X., et al. Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model. Dermatology 2009, 219:232-238.
108. Matthys P., et al. The protective effect of IFN-γ in experimental autoimmune diseases: a central role of mycobacterial adjuvant-induced myelopoiesis. J. Leukoc. Biol. 2000, 68:447-454.
109. Collin M., et al. IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:4265-4270.
110. Smolen J.S., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997.
111. Ward N.S., et al. Interleukin-6-induced protection in hyperoxic acute lung injury. Am. J. Respir. Cell Mol. Biol. 2000, 22:535-542.
112. Fasano, A. et al. University of Maryland, Baltimore. Methods for screening for modulators of CXCR3 signaling, US 7622264.
113. van Wanrooij E.J., et al. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:251-257.
114. Fritzsche J., et al. The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity. Biochem. Pharmacol. 2006, 72:474-485.
115. Allhorn M., Collin M. Sugar-free antibodies - the bacterial solution to autoimmunity?. Ann. N. Y. Acad. Sci. 2009, 1173:664-669.
116. Reichert J.M. Marketed therapeutic antibodies compendium. MAbs 2012, 4:413-415.
117. Ludwig R.J., Schmidt E. Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis?. G. Ital. Dermatol. Venereol. 2009, 144:339-349.